Skip to main content
Signal8
Launch Terminal

IceCure Medical Ltd. (ICCM)

Headquartered in Caesarea, Israel, and founded in 2006, IceCure Medical Ltd is a medical device enterprise dedicated to inventing, refining, and marketing innovative solutions for treating human tumors through cryoablation, a freezing process. Their primary offering, the ProSense system, provides a specialized cryoablation therapy specifically for breast tumors.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Devices

IceCure Medical Ltd logo

IceCure Medical Ltd

NASDAQ:ICCMHealthcare
-9.05%$0.8701
AH$0.9390+7.92%vs close
Mkt Cap$4.04M
Float3.54M
O/S4.64M
Vol
$ Vol
RVOL
Inst Own2.8%
SI1.2%
Earnings
Dilution
IceCure Medical Ltd logoNASDAQ:ICCM$0.8701-9.05%
Phase Distribution
6 lead-sponsored trials·1 active·4 completed
Not applicable6
(1 more as collaborator)
Status Overview
Recruiting1
Completed4
Stopped1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
  • Not applicable
    Completed

    ICE-SENSE™ Cryotherapy for Breast Fibroadenoma Trial

    Ice-Sense

    Fibroadenoma

    Enrollment
    54
    Start
    Apr 2009
    Primary Completion
    Jan 2013
    Completion
    Jan 2013
    NCT00910312
  • Not applicable
    Completed

    Cryotherapy for Breast Cancer Trial

    Ice-Sense3TM

    Breast Carcinoma

    Enrollment
    4
    Start
    Aug 2012
    Primary Completion
    Jul 2014
    Completion
    Jul 2014
    NCT01671943
  • Not applicable
    Withdrawn

    Laparoscopic Cryoablation of Uterine Fibroids

    IceSense3 system

    Symptomatic Uterine Fibroids

    Enrollment
    0
    Start
    Dec 2012
    Primary Completion
    Dec 2015
    Completion
    Dec 2015
    NCT01735812
  • Not applicable
    Completed

    Cryoablation of Low Risk Small Breast Cancer- ICE3 Trial

    Ice-Sense3TM/ ProSenseTM

    Breast Cancer

    Enrollment
    206
    Start
    Oct 2014
    Primary Completion
    Mar 2024
    Completion
    May 2024
    NCT02200705
  • Not applicable
    Completed

    Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma

    PROSENSE™

    Renal Cell Carcinoma

    Enrollment
    120
    Start
    Jul 2014
    Primary Completion
    Feb 2026
    Completion
    Jul 2026
    NCT02399124
  • Not applicable
    Recruiting

    Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)

    Cryoablation

    Low-Risk, Early Stage Breast Cancer

    Enrollment
    400
    Start
    Jul 2026
    Primary Completion
    Jul 2034est.
    Completion
    Sep 2034est.
    NCT07629206
Search ClinicalTrials.gov for “IceCure Medical”